Zomedica Corp. (ZOM) Bundle
An Overview of Zomedica Corp. (ZOM)
General Summary of Zomedica Corp. (ZOM)
Zomedica Corp. is a veterinary diagnostic and pharmaceutical company headquartered in Ann Arbor, Michigan. The company focuses on developing innovative diagnostic and therapeutic products for companion animals.
Key Product Lineup:
- TRUFORMA® diagnostic platform for veterinary diagnostics
- Companion animal diagnostic tests
- Pharmaceutical products for veterinary care
Financial Performance (2023 Fiscal Year)
| Financial Metric | Amount |
|---|---|
| Total Revenue | $4.2 million |
| Net Loss | ($14.3 million) |
| Cash and Cash Equivalents | $22.1 million |
Product Sales Breakdown:
- TRUFORMA® Platform Sales: $2.7 million
- Diagnostic Test Kit Sales: $1.5 million
Industry Leadership
Market Position: Zomedica operates in the veterinary diagnostic equipment and pharmaceutical market, targeting companion animal healthcare.
| Market Segment | Market Share |
|---|---|
| Veterinary Diagnostics | 2.3% |
| Companion Animal Pharmaceuticals | 1.7% |
Company Stock Information (as of January 2024):
- Stock Symbol: ZOM
- Stock Price: $0.23
- Market Capitalization: $126.5 million
Mission Statement of Zomedica Corp. (ZOM)
Mission Statement of Zomedica Corp. (ZOM)
Zomedica Corp. (ZOM) focuses on developing innovative veterinary diagnostic and therapeutic products specifically for companion animals.
Core Mission Components
| Component | Specific Details | 2024 Status |
|---|---|---|
| Veterinary Innovation | Point-of-care diagnostics | Active development pipeline |
| Technology Focus | TRUFORMA® diagnostic platform | Commercialized product |
| Market Segment | Companion animal healthcare | Primary market targeting |
Strategic Product Portfolio
- TRUFORMA® Diagnostic Platform
- Companion Animal Diagnostic Solutions
- Advanced Veterinary Therapeutics
Financial Performance Metrics
| Metric | 2023 Value | 2024 Projection |
|---|---|---|
| Revenue | $3.2 million | $5-7 million projected |
| R&D Investment | $4.5 million | $6 million planned |
Technology Development Focus
Key technological priorities:
- Advanced diagnostic assay development
- Point-of-care testing capabilities
- Precision veterinary medicine technologies
Vision Statement of Zomedica Corp. (ZOM)
Vision Statement Components of Zomedica Corp. (ZOM) in 2024
Veterinary Diagnostic Technology FocusZomedica Corp. aims to develop innovative point-of-care diagnostic solutions for veterinary professionals. As of Q1 2024, the company has developed TRUFORMA® platform for companion animal diagnostics.
| Product | Market Segment | Target Species |
|---|---|---|
| TRUFORMA® | Veterinary Diagnostics | Companion Animals |
Zomedica's vision includes continuous technological advancement in veterinary diagnostic platforms.
- Research & Development Investment: $3.2 million in 2023
- Patent Portfolio: 12 active patents
- Technology Focus Areas: Biomarker detection, immunoassay technologies
Zomedica targets veterinary diagnostic market with specialized technological solutions.
| Market Metric | 2024 Projection |
|---|---|
| Total Addressable Market | $3.6 billion |
| Projected Market Share | 2.5% |
Core Values of Zomedica Corp. (ZOM)
Core Values of Zomedica Corp. (ZOM) in 2024
Innovation in Veterinary DiagnosticsZomedica Corp. demonstrates commitment to innovation through its TRUFORMA® platform, which provides point-of-care diagnostic testing for veterinarians.
| Innovation Metrics | 2024 Data |
|---|---|
| R&D Investment | $3.2 million |
| New Diagnostic Panels Developed | 3 new panels |
| Patent Applications | 5 pending |
Zomedica prioritizes veterinary professional needs through targeted solutions.
- Customer support response time: 2.5 hours
- Customer satisfaction rate: 94%
- Training sessions provided: 42 nationwide
TRUFORMA® platform represents technological leadership in veterinary diagnostics.
| Technology Performance | 2024 Metrics |
|---|---|
| Test Accuracy Rate | 99.6% |
| Processing Speed | 15 minutes per test |
| Connected Veterinary Clinics | 1,237 clinics |
Zomedica focuses on advancing companion animal healthcare through diagnostic technologies.
- Conditions tested: Thyroid, adrenal, and kidney diseases
- Species coverage: Canine and feline
- Clinical partnerships: 28 veterinary research institutions
| Financial Metrics | 2024 Data |
|---|---|
| Revenue | $12.4 million |
| Gross Margin | 62% |
| Operating Expenses | $8.7 million |
Zomedica Corp. (ZOM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.